Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.

被引：17

作者：

Javle, Milind M.

Borbath, Ivan

Clarke, Stephen John

Hitre, Erika

Louvet, Christophe

Mercade, Teresa Macarulla

Oh, Do-Youn

Spratlin, Jennifer L.

Valle, Juan W.

Weiss, Karl Heinz

Berman, Craig

Howland, Michael

Ye, Yining

Cho, Terry

Moran, Susan

Abou-Alfa, Ghassan K.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Clin Univ St Luc Bruxelles, Brussels, Belgium

[3] Univ Sydney, Sydney, NSW, Australia

[4] Natl Inst Oncol, Budapest, Hungary

[5] Inst Mutualiste Montsouris, Paris, France

[6] Vall dHebron Univ Hosp, Barcelona, Spain

[7] Vall dHebron Inst Oncol, Barcelona, Spain

[8] Seoul Natl Univ Hosp, Seoul, South Korea

[9] Alberta Hlth Serv, Edmonton, AB, Canada

[10] Univ Manchester, Christie, Manchester, Lancs, England

[11] Univ Hosp Heidelberg, Heidelberg, Germany

[12] QED Therapeut Inc, San Francisco, CA USA

[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.TPS4155

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4155

引用

页数：2